SCHEMBL30788367

SCHEMBL30788367

CC(=O)N[C@@H](C[SeH])C(=O)N[C@@H](C[SeH])C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C[SeH])C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C[SeH])C(N)=O

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 4/20 0.56
▸ NMUR2 Q9GZQ4 5/20 0.56
▸ NMUR1 Q9HB89 5/20 0.56
▸ TFPI P10646 4/20 0.55
▸ CTSL P07711 3/20 0.53
▸ CTSS P25774 3/20 0.53
▸ CTSK P43235 3/20 0.53
▸ CTSH P09668 1/20 0.53
▸ C5AR1 P21730 1/20 0.52
▸ EPHA2 P29317 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30788370 0.96 TFPI (0.59) F2NMUR2NMUR1TFPICTSL
SCHEMBL30788362 0.94 F2 (0.56) F2NMUR2NMUR1TFPICTSL
SCHEMBL30788365 0.93 F2 (0.58) F2NMUR2NMUR1TFPICTSL
SCHEMBL30753757 0.92 NMUR2 (0.58) F2NMUR2NMUR1C5AR1EPHA2
SCHEMBL30788359 0.91 CTSL (0.56) F2NMUR2NMUR1TFPICTSL
SCHEMBL30788357 0.91 TFPI (0.59) F2TFPIC5AR1
SCHEMBL30788366 0.89 C5AR1 (0.58) TFPICTSLCTSSCTSKCTSH
SCHEMBL30788369 0.89 C5AR1 (0.57) TFPICTSLCTSSCTSKCTSH
SCHEMBL30753758 0.89 C5AR1 (0.63) F2NMUR2NMUR1TFPIC5AR1
SCHEMBL30788343 0.88 F2 (0.57) F2TFPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240139089-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS GLO PHARMA, INC. 2024-05-02 — — US disclosed
US-20240122823-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS GLO PHARMA, INC. 2024-04-18 — — US disclosed
US-20240076314-A1 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY GLO PHARMA, INC. 2024-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139089-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS LIPA, PLIN5, PLIN3 F2 3370/4885NMUR2 1728/4885NMUR1 2016/4885
US-20240076314-A1 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY CHRNB1, CHRNG, CHRNA1 F2 2151/4885NMUR2 27/4885NMUR1 22/4885
US-20240122823-A1 MULTISOME LIPID VESICLES FOR DELIVERY OF COSMETIC AGENTS LIPA, PLIN5, LIPE F2 3567/4885NMUR2 2354/4885NMUR1 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback